Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar;157(3):1249-1259.e5.
doi: 10.1016/j.jtcvs.2018.09.136. Epub 2018 Nov 24.

Patterns and risk of recurrence in patients with esophageal cancer with a pathologic complete response after chemoradiotherapy followed by surgery

Arianna Barbetta  1 , Smita Sihag  1 , Tamar Nobel  1 , Meier Hsu  2 , Kay See Tan  2 , Manjit Bains  1 , David R Jones  1 , Daniela Molena  3
Affiliations

Patterns and risk of recurrence in patients with esophageal cancer with a pathologic complete response after chemoradiotherapy followed by surgery

Arianna Barbetta et al. J Thorac Cardiovasc Surg. 2019 Mar.

Abstract

Objectives: A pathologic complete response in patients with locally advanced esophageal cancer after chemoradiotherapy and surgery is associated with improved overall and disease-free survival. Nevertheless, approximately one third of patients with a pathologic complete response still have a recurrence. The aim of this study was to evaluate risk factors and patterns of recurrence in patients with locally advanced esophageal cancer who achieved a pathologic complete response after chemoradiotherapy and surgery.

Methods: We performed a retrospective review of a single-institution database of 233 patients with stage II and III esophageal cancer with a pathologic complete response after chemoradiotherapy and surgery between 1997 and 2017. A multivariable competing risk-regression model was used to identify predictors of recurrence.

Results: A total of 61 patients exhibited recurrence in this cohort, 43 with adenocarcinoma and 18 with squamous cell carcinoma. Five-year cumulative incidence of recurrence did not vary by histology. Univariable analysis revealed that poor tumor differentiation (hazard ratio, 2.28; P = .022) and advanced clinical stage (hazard ratio, 1.89; P = .042) are predictors of recurrence in the esophageal adenocarcinoma subgroup, whereas poor tumor differentiation remained the only independent predictor on multivariable analysis in the entire cohort (hazard ratio, 2.28; P = .009). Patients with esophageal adenocarcinoma had a higher incidence of distant recurrences, and patients with esophageal squamous cell carcinoma demonstrated a higher incidence of loco-regional recurrence (P = .039).

Conclusions: Poor tumor differentiation is an independent risk factor for recurrence in patients with esophageal cancer with a pathologic complete response. Although there is no difference in the cumulative incidence of recurrence between esophageal adenocarcinoma and esophageal squamous cell carcinoma, patterns of recurrence appear to differ. Thus, treatment and surveillance strategies may be tailored appropriately.

Keywords: esophageal cancer; neoadjuvant chemoradiotherapy plus surgery; pathologic complete response; recurrence; survival.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors have no conflicts of interest.

Figures

Figure 1 –
Figure 1 –
Cumulative incidence of recurrence (CIR) stratified by histology. There was no significant difference in the cumulative incidence of disease recurrence between adenocarcinoma (adeno) and squamous cell carcinoma (SCC) histologies.
Figure 2 –
Figure 2 –
Cumulative incidence of distant recurrence (CIDR; A) and loco-regional recurrence (B) stratified by histology. A, Patients with adenocarcinoma (adeno) had a higher incidence of distant recurrences than patients with squamous cell carcinoma (SCC), though not statistically significant. B, Conversely, patients with SCC had a higher incidence of loco-regional recurrence than patients with adeno, and this was statistically significant.
Figure 3 –
Figure 3 –
Overall survival (OS) following recurrence stratified by interval to recurrence. OS was significantly lower in patients that recurred within 6 months post-treatment in comparison to those that recurred beyond this window.
Central Picture:
Central Picture:
Cumulative incidence of recurrence after pathologic complete response, by histology.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074–2084. - PubMed
    1. Liu B, Bo Y, Wang K, et al. Concurrent neoadjuvant chemoradiotherapy could improve survival outcomes for patients with esophageal cancer: a meta-analysis based on random clinical trials. Oncotarget 2017;8:20410–20417. - PMC - PubMed
    1. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. The Lancet Oncology 2007;8:226–234. - PubMed
    1. Napier KJ, Scheerer M, Misra S. Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol 2014;6:112–120. - PMC - PubMed
    1. Cancer Genome Atlas Research N, Analysis Working Group: Asan U, Agency BCC, et al. Integrated genomic characterization of oesophageal carcinoma. Nature 2017;541:169–175. - PMC - PubMed